ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open- label, multicenter phase 2 basket study

Xia, Lingfang; Peng, Jin; Lou, Ge; Pan, Mei; Zhou, Qi; Hu, Wenjing; Shi, Huirong; Wang, Li; Gao, Yunong; Zhu, Jianqing; Zhang, Yu; Sun, Rong; Zhou, Xianfeng; Wang, Quanren; Wu, Xiaohua*复旦大学; 山东大学; 哈尔滨医科大学; 郑州大学; 重庆大学; 中国科学院研究生院; 1
Journal for ImmunoTherapy of Cancer2022-1DOI: 10.1136/jitc-2021-003831
18被引5阅读
引用收藏
分享

摘要

Background Combination treatments with immunecheckpoint inhibitor and antiangiogenic therapy have the potential for synergistic activity through modulation of the microenvironment and represent a notable therapeutic strategy in recurrent ovarian cancer (ROC). We report the results of camrelizumab (an anti-programmed cell death protein-1 antibody) in combination with famitinib (a receptor tyrosine kinase inhibitor) for the treatment of platinum-resistant ROC from an open-label, multicenter, phase 2 basket trial. @@@ Methods Eligible patients with platinum-resistant ROC were enrolled to receive camrelizumab (200 mg every 3 weeks by intravenous infusion) and oral famitinib (20 mg once daily). All patients had disease progression during or <6 months after their most recent platinum-based chemotherapy. Primary endpoint was confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 based on investigator's assessment. Secondary endpoints included disease control rate (DCR), duration of response (DoR), time to response (TTR), progression-free survival (PFS), overall survival (OS), 12-month OS rate and safety profile. @@@ Results Of the 37women enrolled, 11 (29.7%) patients had primary platinum resistant, 15 (40.5%) patients had secondary platinum resistant and 11 (29.7%) patients had primary platinum refractory disease. As the cut-off date of April 9, 2021, nine (24.3%) patients had achieved a confirmed objective response, the ORR was 24.3% (95% CI, 11.8 to 41.2) and the DCR was 54.1% (95% CI, 36.9 to 70.5). Patients with this combination regimen showed a median TTR of 2.1 months (range, 1.8-4.1) and a median DoR of 4.1 months (95% CI, 1.9 to 6.3). Median PFS was 4.1 months (95% CI, 2.1 to 5.7), and median OS was 18.9 months (95% CI, 10.8 to not reached), with the median follow-up duration of 22.0 months (range, 12.0-23.7). The estimated 12-month OS rate was 67.2% (95% CI, 49.4 to 79.9). The most common 4rade 3 treatment-related adverse events were hypertension (32.4%), decreased neutrophil count (29.7%) and decreased platelet count (13.5%). One (2.7%) patient died of grade 5 hemorrhage that was judged possibly related to study treatment by investigator. @@@ Conclusion The carnrelizurnab with famitinib combination appeared to show antitumor activity in heavily pretreated patients with platinum-resistant ROC with an acceptable safety profile. This combination might provide a novel alternative treatment strategy in platinum-resistant ROC setting and warranted further exploration.

学科与关键词

关键词
T-CELLSCOMBINATIONCHEMOTHERAPYINHIBITORANTIBODY
相关
加载中…
  • First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS &ge;1%: results from a multicenter, open-label, phase 2 trial
    Ren, Shengxiang; Wang, Xicheng; Han, Bao-Hui; Pan, Yueyin; Zhao, Jun; Cheng, Yufeng; Hu, Sheng; Liu, Tianshu; Li, Yalun; Cheng, Ying; Feng, Jifeng; Yi, Shanyong; Gu, Shanzhi; Gao, Shegan; Luo, Yongzhong; Liu, Ying; Liu, Caigang; Duan, Huijie; Wang, Shuni; Yang, Xinfeng; Fan, Jia*; Zhou, Caicun*Journal for ImmunoTherapy of Cancer, 2024, 12(2): e007227.
  • A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma
    Xia, Lingfang; Zhou, Qi; Gao, Yunong; Hu, Wenjing; Lou, Ge; Sun, Hong; Zhu, Jianqing; Shu, Jin; Zhou, Xianfeng; Sun, Rong; Wu, Xiaohua*Nature Communications, 2022, 13(1): 7581.被引 7
  • Camrelizumab plus famitinib as first-line treatment in advanced NSCLC patients with PD-L1 TPS &ge;1%: A report from a multicenter, open-label, phase II basket trial
    Ren, S.; Wang, X.; Han, B.; Pan, Y.; Zhao, J.; Cheng, Y.; Hu, S.; Liu, T.; Li, Y.; Cheng, Y.; Feng, J.; Yi, S.; Gu, S.; Gao, S.; Luo, Y.; Liu, Y.; Liu, C.; Duan, H.; Zhou, C.; Fan, J.
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal for ImmunoTherapy of Cancer
发表日期
2022-01
卷期
第 10 卷, 第 1 期
页码
e003831
DOI
10.1136/jitc-2021-003831
期刊等级
2区
成果收录
SCIE
资助标注
Jiangsu Hengrui Pharmaceuticals Co., Ltd.

作者

  • X

    Xia, Lingfang (第一作者)

    fudan univ

  • P

    Peng, Jin

    shandong univ

查看全部 15 位作者收起作者
  • L

    Lou, Ge

    harbin med univ

  • P

    Pan, Mei

    jiangxi maternal & child hlth hosp

  • Z

    Zhou, Qi

    chongqing univ

  • H

    Hu, Wenjing

  • S

    Shi, Huirong

    1 · zhengzhou univ

  • W

    Wang, Li

    zhengzhou univ

  • G

    Gao, Yunong

  • Z

    Zhu, Jianqing

    univ chinese acad sci · zhejiang canc hosp

  • Z

    Zhang, Yu

  • S

    Sun, Rong

  • Z

    Zhou, Xianfeng

  • W

    Wang, Quanren

  • W

    Wu, Xiaohua (通讯)

    fudan univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417